Profile picture

Mr Christopher Schneider

Graz (Austria)
Follow
Logo ESC

Contributor content

The anti-cancer tyrosine kinase inhibitor sorafenib reduces cardiac contractile force by reducing cardiomyocyte calcium transient amplitude.
Presentation
The anti-cancer tyrosine kinase inhibitor sorafenib reduces cardiac contractile force by reducing cardiomyocyte calcium transient amplitude.
Read more

ESC 365 is supported by

novartis Explore sponsored resources